Are there any risks in prosecuting claims relating to alternative embodiments of a biotechnological invention in a European patent application?

Biotechnology Law Report

Volumn 19, Issue 3, 2000, Pages 310-

  Jaenichen, Hans Rainer ^a   Steinecke, Peter ^a  

^a Vossius and Partner   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 19844372189     PISSN: 0730031X     EISSN: None     Source Type: Journal    
DOI: 10.1089/07300310050051816     Document Type: Article

References (4)

1. See landmark decision T301/87 "α-interferons/BIOGEN, " OJ EPO 1990 335.
2. See also EP-B1 148 605 (T412/93 "Erythropoietin/AMGEN;" not published in the OJ EPO)
3. EP-B1 93 619 (T923/92 "Human t-PA/GENENTECH, " OJ EPO 1996 564)
4. and EP-B1 91 539 (T128/92 "Interleukin-2/AJINOMOTO;" not published in the OJ EPO) which define the claimed DNA in alternative sections.